HomeCompareFTMRQ vs JNJ

FTMRQ vs JNJ: Dividend Comparison 2026

FTMRQ yields 2000000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FTMRQ wins by $4.879226400974806e+39M in total portfolio value
10 years
FTMRQ
FTMRQ
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full FTMRQ calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — FTMRQ vs JNJ

📍 FTMRQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFTMRQJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FTMRQ + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FTMRQ pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FTMRQ
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, FTMRQ beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FTMRQ + JNJ for your $10,000?

FTMRQ: 50%JNJ: 50%
100% JNJ50/50100% FTMRQ
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

FTMRQ
No analyst data
Altman Z
-2.1
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FTMRQ buys
0
JNJ buys
0
No recent congressional trades found for FTMRQ or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFTMRQJNJ
Forward yield2000000.00%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$4.879226400974806e+39M$30.3K
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$4,689.40
Total dividends collected$4.879195005460081e+39M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FTMRQ vs JNJ ($10,000, DRIP)

YearFTMRQ PortfolioFTMRQ Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$200,010,700$200,000,000.00$10,592$272.30+$200.00MFTMRQ
2$3,738,731,768,458$3,738,517,757,009.35$11,289$357.73+$3738731.76MFTMRQ
3$65,315,062,866,930,490$65,311,062,423,938,240.00$12,123$472.89+$65315062866.92MFTMRQ
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$13,141$629.86+$1066400830062625.00MFTMRQ
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$14,408$846.81+$16272182796453826560.00MFTMRQ
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$16,021$1,151.60+$2.3205424011366188e+23MFTMRQ
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$18,122$1,588.22+$3.0927990661046884e+27MFTMRQ
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$20,930$2,228.20+$3.8524105697352695e+31MFTMRQ
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$24,792$3,191.91+$4.484688260147987e+35MFTMRQ
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$30,274$4,689.40+$4.879226400974806e+39MFTMRQ

FTMRQ vs JNJ: Complete Analysis 2026

FTMRQStock

Fortem Resources Inc. engages in the acquisition, exploration, and development of oil and gas properties in Canada and the United States. It holds 100% interest in the Godin property covering an area of approximately 12,800 located in the Godin area of Northern Alberta. The company also holds 75% interest in the Black Dragon property covering an area of 150,178 acres located in the Moenkopi formation of the Carbon and Emery Counties, Utah; and 75% interest in the Rolling Rock Property covering an area of 130,942 acres located in the Mancos formation in the Southern Uinta Basin, Utah. In addition, it holds 100% interest in the City of Gold mineral mining project in Myanmar. The company was formerly known as Strongbow Resources Inc. and changed its name to Fortem Resources Inc. in March 2017. Fortem Resources Inc. was founded in 2004 and is based in Calgary, Canada. On February 2, 2022, the voluntary petition of Fortem Resources Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on October 5, 2021.

Full FTMRQ Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this FTMRQ vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FTMRQ vs SCHDFTMRQ vs JEPIFTMRQ vs OFTMRQ vs KOFTMRQ vs MAINFTMRQ vs ABBVFTMRQ vs MRKFTMRQ vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.